Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 90

1.

A Tandem Oligonucleotide Approach for SNP-Selective RNA Degradation Using Modified Antisense Oligonucleotides.

Magner D, Biala E, Lisowiec-Wachnicka J, Kierzek E, Kierzek R.

PLoS One. 2015 Nov 6;10(11):e0142139. doi: 10.1371/journal.pone.0142139. eCollection 2015.

2.

Analysis by a highly sensitive split luciferase assay of the regions involved in APP dimerization and its impact on processing.

Decock M, El Haylani L, Stanga S, Dewachter I, Octave JN, Smith SO, Constantinescu SN, Kienlen-Campard P.

FEBS Open Bio. 2015 Sep 6;5:763-73. doi: 10.1016/j.fob.2015.09.002. eCollection 2015.

3.

Amyloid β-Protein Assembly: Differential Effects of the Protective A2T Mutation and Recessive A2V Familial Alzheimer's Disease Mutation.

Zheng X, Liu D, Roychaudhuri R, Teplow DB, Bowers MT.

ACS Chem Neurosci. 2015 Oct 21;6(10):1732-40. doi: 10.1021/acschemneuro.5b00171. Epub 2015 Aug 12.

4.

Two distinct β-sheet structures in Italian-mutant amyloid-beta fibrils: a potential link to different clinical phenotypes.

Hubin E, Deroo S, Schierle GK, Kaminski C, Serpell L, Subramaniam V, van Nuland N, Broersen K, Raussens V, Sarroukh R.

Cell Mol Life Sci. 2015 Dec;72(24):4899-913. doi: 10.1007/s00018-015-1983-2. Epub 2015 Jul 21.

5.

The Maze of APP Processing in Alzheimer's Disease: Where Did We Go Wrong in Reasoning?

Chen M.

Front Cell Neurosci. 2015 May 28;9:186. doi: 10.3389/fncel.2015.00186. eCollection 2015. Review.

6.

Alternative salt bridge formation in Aβ-a hallmark of early-onset Alzheimer's disease?

Schledorn M, Meier BH, Böckmann A.

Front Mol Biosci. 2015 Apr 28;2:14. doi: 10.3389/fmolb.2015.00014. eCollection 2015.

7.

Pharmacological inhibition of O-GlcNAcase (OGA) prevents cognitive decline and amyloid plaque formation in bigenic tau/APP mutant mice.

Yuzwa SA, Shan X, Jones BA, Zhao G, Woodward ML, Li X, Zhu Y, McEachern EJ, Silverman MA, Watson NV, Gong CX, Vocadlo DJ.

Mol Neurodegener. 2014 Oct 26;9:42. doi: 10.1186/1750-1326-9-42.

8.

Genetic heterogeneity in Alzheimer disease and implications for treatment strategies.

Ringman JM, Goate A, Masters CL, Cairns NJ, Danek A, Graff-Radford N, Ghetti B, Morris JC; Dominantly Inherited Alzheimer Network.

Curr Neurol Neurosci Rep. 2014 Nov;14(11):499. doi: 10.1007/s11910-014-0499-8. Review.

9.

Serial propagation of distinct strains of Aβ prions from Alzheimer's disease patients.

Watts JC, Condello C, Stöhr J, Oehler A, Lee J, DeArmond SJ, Lannfelt L, Ingelsson M, Giles K, Prusiner SB.

Proc Natl Acad Sci U S A. 2014 Jul 15;111(28):10323-8. doi: 10.1073/pnas.1408900111. Epub 2014 Jun 30.

10.

Clinical genetics of Alzheimer's disease.

Zou Z, Liu C, Che C, Huang H.

Biomed Res Int. 2014;2014:291862. doi: 10.1155/2014/291862. Epub 2014 May 13. Review.

11.

Effect of the English familial disease mutation (H6R) on the monomers and dimers of Aβ40 and Aβ42.

Viet MH, Nguyen PH, Derreumaux P, Li MS.

ACS Chem Neurosci. 2014 Aug 20;5(8):646-57. doi: 10.1021/cn500007j. Epub 2014 Jun 30.

12.

Early-onset formation of parenchymal plaque amyloid abrogates cerebral microvascular amyloid accumulation in transgenic mice.

Xu F, Kotarba AE, Ou-Yang MH, Fu Z, Davis J, Smith SO, Van Nostrand WE.

J Biol Chem. 2014 Jun 20;289(25):17895-908. doi: 10.1074/jbc.M113.536565. Epub 2014 May 14.

13.

BACE1 (β-secretase) inhibitors for the treatment of Alzheimer's disease.

Ghosh AK, Osswald HL.

Chem Soc Rev. 2014 Oct 7;43(19):6765-813. doi: 10.1039/c3cs60460h. Review.

14.

Amyloidosis associated with cerebral amyloid angiopathy: cell signaling pathways elicited in cerebral endothelial cells.

Ghiso J, Fossati S, Rostagno A.

J Alzheimers Dis. 2014;42 Suppl 3:S167-76. doi: 10.3233/JAD-140027. Review.

15.

Conformational changes induced by the A21G Flemish mutation in the amyloid precursor protein lead to increased Aβ production.

Tang TC, Hu Y, Kienlen-Campard P, El Haylani L, Decock M, Van Hees J, Fu Z, Octave JN, Constantinescu SN, Smith SO.

Structure. 2014 Mar 4;22(3):387-96. doi: 10.1016/j.str.2013.12.012. Epub 2014 Jan 23.

16.

Neprilysin and Aβ Clearance: Impact of the APP Intracellular Domain in NEP Regulation and Implications in Alzheimer's Disease.

Grimm MO, Mett J, Stahlmann CP, Haupenthal VJ, Zimmer VC, Hartmann T.

Front Aging Neurosci. 2013 Dec 23;5:98. doi: 10.3389/fnagi.2013.00098. Review.

17.

Internal and environmental effects on folding and dimerization of the Alzheimer's β amyloid peptide.

Anand P, Hansmann UH.

Mol Simul. 2011 May 1;37(6). doi: 10.1080/08927022.2011.551879.

18.

Adjusting the compass: new insights into the role of angiogenesis in Alzheimer's disease.

Jefferies WA, Price KA, Biron KE, Fenninger F, Pfeifer CG, Dickstein DL.

Alzheimers Res Ther. 2013 Dec 19;5(6):64. doi: 10.1186/alzrt230. eCollection 2013. Review.

19.

Stability of transmembrane amyloid β-peptide and membrane integrity tested by molecular modeling of site-specific Aβ42 mutations.

Poojari C, Strodel B.

PLoS One. 2013 Nov 7;8(11):e78399. doi: 10.1371/journal.pone.0078399. eCollection 2013.

20.

Effect of the Tottori familial disease mutation (D7N) on the monomers and dimers of Aβ40 and Aβ42.

Viet MH, Nguyen PH, Ngo ST, Li MS, Derreumaux P.

ACS Chem Neurosci. 2013 Nov 20;4(11):1446-57. doi: 10.1021/cn400110d. Epub 2013 Sep 16.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk